| 1 |
Azarmi M, Maleki H, Nikkam N, Malekinejad H. Transcellular brain drug delivery: A review on recent advancements. International Journal of Pharmaceutics 2020;586:119582. [DOI: 10.1016/j.ijpharm.2020.119582] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 2 |
Cun D, Zhang C, Bera H, Yang M. Particle engineering principles and technologies for pharmaceutical biologics. Adv Drug Deliv Rev 2021;174:140-67. [PMID: 33845039 DOI: 10.1016/j.addr.2021.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 3 |
Tesarova B, Musilek K, Rex S, Heger Z. Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery. Journal of Controlled Release 2020;325:176-90. [DOI: 10.1016/j.jconrel.2020.06.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 4 |
Han J, Yu S. Screening for a suitable cell membrane anchoring tag for Pseudomonas aeruginosa and applying it in cell membrane real-time tracking to investigate membrane aging. J Microbiol Methods 2020;175:105984. [PMID: 32561163 DOI: 10.1016/j.mimet.2020.105984] [Reference Citation Analysis]
|
| 5 |
Agarwal M, Mondal T, Bose B. Peptides derived from a short stretch of diphtheria toxin bind to heparin-binding epidermal growth factor-like growth factor. Toxicon 2019;169:109-16. [PMID: 31494209 DOI: 10.1016/j.toxicon.2019.09.006] [Reference Citation Analysis]
|
| 6 |
Khan AR, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release 2018;291:37-64. [DOI: 10.1016/j.jconrel.2018.10.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 7 |
Rabha B, Bharadwaj KK, Baishya D, Sarkar T, Edinur HA, Pati S. Synthesis and Characterization of Diosgenin Encapsulated Poly-ε-Caprolactone-Pluronic Nanoparticles and Its Effect on Brain Cancer Cells. Polymers (Basel) 2021;13:1322. [PMID: 33919483 DOI: 10.3390/polym13081322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer. Mol Pharm 2018;15:1495-504. [PMID: 29502423 DOI: 10.1021/acs.molpharmaceut.7b01055] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
|
